COMPANY PROFILE // THE 014 REPORT
Neonc Technologies Holdings, Inc.
NTHI (Nasdaq)
Assembled from 3 government sources in 0.3 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Red8-K Item 4.02 filed: non-reliance on previously issued financial statements on 2025-08-20 and 1 more time (last 24 months).
- Amber4 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-10-15: a pattern of leadership change.
- AmberNT 10-Q filed on 2025-08-14: notice that a periodic report would be late.
- Amber8-K Item 4.01 filed: change in the company's certifying accountant (auditor) on 2025-04-01 (last 24 months).
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
NEONC TECHNOLOGIES HOLDINGS, INC. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Calabasas, CA; listed as NTHI (Nasdaq).[source] It reported revenue of $39,990 for the fiscal year ended 2025-12-31.[source] It has filed 103 documents with the SEC in the last 12 months; the latest is Form 8-K, filed 2026-11-18.[source] Its largest institutional holders on 13F filings are Cinctive Capital Management LP, VANGUARD CAPITAL MANAGEMENT LLC, BANK OF AMERICA CORP /DE/ (as of 2026-06-30).[source] Seraphix flags 4 items from these records: 8-K Item 4.02 filed; 8-K Item 4.01 filed; 4 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-10-15.[source]
- red1
- amber3
- info0
- Cinctive Capital Management LP$7.3M
- VANGUARD CAPITAL MANAGEMENT LLC$2.3M
- BANK OF AMERICA CORP /DE/$1.0M
- Westmount Partners, LLC$893K
- BlackRock, Inc.$815K
- GEODE CAPITAL MANAGEMENT, LLC$753K
- VANGUARD FIDUCIARY TRUST CO$414K
- STATE STREET CORP$196K
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- CHEN THOMAS C · CEO (Director,Officer,10% owner) · latest Form 4/A 2025-06-05 · filing · LinkedIn search
- GARNETT KEITHLY · CFO (Director,Officer) · latest Form 4/A 2025-06-05 · filing · LinkedIn search
- Heshmatpour Amir F · President (Director,Officer,10% owner) · latest Form 4 2025-11-24 · filing · LinkedIn search
- Neman-Ebrahim Yousha · Chief Clinical Officer (Officer) · latest Form 4 2025-11-24 · filing · LinkedIn search
- WALTERS PATRICK · COO (Officer) · latest Form 4/A 2025-06-05 · filing · LinkedIn search
- CHIANG MING-FU (ALAN) · Director · latest Form 3 2025-11-24 · filing · LinkedIn search
- Delshad Jim · Director · latest Form 4 2025-05-19 · filing · LinkedIn search
- PURI ISHWAR KANWAR · Director · latest Form 3 2025-09-05 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001979414 | source |
| EIN | 92-1954864 | source |
| Business address (SEC) | 23975 PARK SORRENTO, SUITE 205, CALABASAS, CA, 91302 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 129 days · Next 10-K due (period ended 2026-12-31; <br>Emerging growth company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 174 days · Next 10-Q due (period ended 2027-03-31; <br>Emerging growth company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
ADDRESS · ZIP CODE
Location context
At the same address (3)
- Marcus & Millichap, Inc. · SEC registrant
- HEARTHSTONE-BUILDER AWARD FOUNDATION · IRS-registered organization
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
SEC registrants at the same address
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-18 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-11-17 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-11-13 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-11-05 filing 8-K items 2.02,7.01,9.01 · SEC EDGAR
- 2026-11-05 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-03 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-10-22 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-10-15 officer change 8-K items 5.02,7.01,9.01 · SEC EDGAR
- 2026-09-28 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-09-21 filing 8-K items 3.03,5.03,7.01,9.01 · SEC EDGAR
- 2026-09-17 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-09-15 filing 144 · SEC EDGAR
- 2026-09-10 filing 8-K items 1.01,7.01,9.01 · SEC EDGAR
- 2026-09-10 filing 424B5 · SEC EDGAR
- 2026-08-21 officer change 8-K/A items 5.02 · SEC EDGAR
- 2026-08-20 filing 8-K items 5.07 · SEC EDGAR
- 2026-08-13 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-08-12 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-08-10 filing 8-K items 2.02,7.01,9.01 · SEC EDGAR
- 2026-08-10 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-07-15 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-07-02 officer change 8-K items 5.02 · SEC EDGAR
- 2026-06-25 filing D · SEC EDGAR
- 2026-06-23 filing EFFECT · SEC EDGAR
- 2026-06-23 filing DEFA14A · SEC EDGAR
- 2026-06-23 filing Proxy statement · SEC EDGAR
- 2026-06-23 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-06-23 filing 424B5 · SEC EDGAR
- 2026-06-18 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-06-15 filing S-3 · SEC EDGAR
123 earlier entries
- 2026-06-12 filing 8-K items 1.01,3.02,3.03,5.03,9.01
- 2026-06-11 filing PRE 14A
- 2026-05-18 filing 8-K items 2.02,7.01,9.01
- 2026-05-15 filing Quarterly report (10-Q)
- 2026-05-05 filing 10-K/A
- 2026-04-24 filing 8-K items 1.01,3.02,9.01
- 2026-04-16 filing EFFECT
- 2026-04-16 filing 8-K items 7.01,9.01
- 2026-04-16 filing 424B5
- 2026-04-14 filing CORRESP
- 2026-04-14 filing UPLOAD
- 2026-04-10 filing S-3
- 2026-04-10 filing 8-K items 1.01,9.01
- 2026-04-10 filing 424B5
- 2026-04-09 filing EFFECT
- 2026-04-07 filing CORRESP
- 2026-04-07 filing UPLOAD
- 2026-04-03 filing 8-K items 2.02,7.01,9.01
- 2026-04-02 filing S-3
- 2026-03-31 filing Annual report (10-K)
- 2026-03-23 filing 8-K items 1.01,3.02,9.01
- 2026-03-17 officer change 8-K items 1.01,5.02,7.01,9.01
- 2026-03-06 filing 8-K items 7.01,9.01
- 2026-03-04 filing 8-K items 8.01
- 2026-03-03 filing 8-K items 1.01,3.02,9.01
- 2026-02-27 filing 8-K items 7.01,9.01
- 2026-02-12 filing EFFECT
- 2026-02-12 filing 424B5
- 2026-02-10 filing CORRESP
- 2026-02-10 filing UPLOAD
- 2026-02-09 filing D
- 2026-02-06 filing Registration (S-1)
- 2026-01-29 filing 8-K items 1.01,3.02,9.01
- 2025-12-23 filing EFFECT
- 2025-12-23 filing 424B5
- 2025-12-19 filing CORRESP
- 2025-12-18 filing D
- 2025-12-17 filing 8-K items 7.01,9.01
- 2025-12-15 filing Registration (S-1)
- 2025-12-05 filing 8-K items 1.01,3.02,7.01,9.01
- 2025-11-21 filing 3/A
- 2025-11-14 officer change 8-K items 2.02,5.02,7.01,9.01
- 2025-11-14 filing Quarterly report (10-Q)
- 2025-11-13 filing 424B4
- 2025-11-12 filing 8-K items 7.01,9.01
- 2025-11-10 filing 8-K items 7.01,9.01
- 2025-11-06 officer change 8-K items 5.02,7.01,9.01
- 2025-10-30 filing 8-K items 7.01,9.01
- 2025-10-10 filing 8-K items 7.01,9.01
- 2025-10-09 filing 8-K items 1.01,7.01,9.01
- 2025-09-11 filing 8-K items 7.01,9.01
- 2025-09-05 insider First Form 3/4/5 on record for PURI ISHWAR KANWAR (Director)
- 2025-08-22 officer change 8-K items 1.01,2.01,2.02,3.02,5.02,7.01,9.01
- 2025-08-20 filing UPLOAD
- 2025-08-20 filing 8-K/A items 4.02
- 2025-08-19 filing UPLOAD
- 2025-08-18 filing Quarterly report (10-Q)
- 2025-08-18 filing 8-K items 4.02
- 2025-08-14 filing NT 10-Q
- 2025-08-13 filing 8-K items 7.01,9.01
- 2025-08-01 filing 8-K items 1.01,7.01,9.01
- 2025-07-30 filing 8-K items 1.01,9.01
- 2025-07-25 filing 8-K items 7.01,9.01
- 2025-07-22 filing 8-K items 1.01,2.03,3.02,9.01
- 2025-07-10 filing 8-K items 7.01,9.01
- 2025-06-16 filing EFFECT
- 2025-06-16 filing 424B5
- 2025-06-12 filing CORRESP
- 2025-06-12 filing 8-K items 7.01,9.01
- 2025-06-12 filing UPLOAD
- 2025-06-09 insider First Form 3/4/5 on record for Neman-Ebrahim Yousha (Chief Clinical Officer)
- 2025-06-06 filing Registration (S-1)
- 2025-06-06 officer change 8-K items 1.01,5.02,9.01
- 2025-06-03 officer change 8-K items 5.02
- 2025-05-19 insider First Form 3/4/5 on record for Delshad Jim (Director)
- 2025-05-09 filing Quarterly report (10-Q)
- 2025-05-06 filing EFFECT
- 2025-05-06 filing 424B5
- 2025-05-02 filing CORRESP
- 2025-05-02 filing UPLOAD
- 2025-04-29 filing Registration (S-1)
- 2025-04-25 filing SCHEDULE 13D
- 2025-04-11 filing D
- 2025-04-11 officer change 8-K items 1.01,5.02,7.01,9.01
- 2025-04-08 insider First Form 3/4/5 on record for CHEN THOMAS C (CEO)
- 2025-04-08 insider First Form 3/4/5 on record for GARNETT KEITHLY (CFO)
- 2025-04-08 insider First Form 3/4/5 on record for Heshmatpour Amir F (President)
- 2025-04-08 insider First Form 3/4/5 on record for WALTERS PATRICK (COO)
- 2025-04-08 insider First Form 3/4/5 on record for CHIANG MING-FU (ALAN) (Director)
- 2025-04-01 filing 8-K items 1.01,3.02,7.01,9.01
- 2025-04-01 filing 8-K items 4.01,9.01
- 2025-03-27 filing 8-K items 5.03,8.01,9.01
- 2025-03-26 filing CERT
- 2025-03-25 filing EFFECT
- 2025-03-25 filing S-8
- 2025-03-25 filing 424B4
- 2025-03-24 filing 8-A12B
- 2025-03-24 filing D
- 2025-03-21 filing CORRESP
- 2025-02-26 filing S-1/A
- 2025-02-26 filing CORRESP
- 2025-02-11 filing UPLOAD
- 2025-01-31 filing S-1/A
- 2025-01-30 filing CORRESP
- 2025-01-03 filing Registration (S-1)
- 2025-01-02 filing CORRESP
- 2024-12-20 filing UPLOAD
- 2024-12-10 filing DRS/A
- 2024-12-09 filing CORRESP
- 2024-11-27 filing UPLOAD
- 2024-10-29 filing DRS
- 2024-10-28 filing D
- 2024-06-12 filing RW
- 2024-03-01 filing FWP
- 2024-03-01 filing S-1/A
- 2024-02-23 filing S-1/A
- 2024-02-05 filing S-1/A
- 2024-01-16 filing S-1/A
- 2023-12-18 filing Registration (S-1)
- 2023-09-27 filing DRS/A
- 2023-08-09 filing DRS/A
- 2023-07-05 filing D
- 2023-06-22 filing DRS
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-18 (within 7 days) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-17 (within 7 days) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-13 (within 30 days) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-05 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-05 (within 30 days) 10-Q filed
- 2026-11-03 (within 30 days) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-22 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-15 (older) 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-22; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:NTHI The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
0 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1979414 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | NTHI / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 921954864 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001979414 | SEC EDGAR / IRS |
| CUSIP | 64051A101 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001979414 | SEC EDGAR |
| UEI | XLZVF5LX5JM8 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001979414 | USAspending |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $39,990 | 2025-12-31 | 10-K, XBRL Revenues | as filed | 2026-11-22 03:11 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$62,146,210 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-22 03:11 UTC | Report an error |
| Total assets (at 2025-12-31) | $2,823,634 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-22 03:11 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | -$17,507,729 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-22 03:11 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $58,729 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-22 03:11 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-22 03:11 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-22 03:11 UTC | Report an error |
| State of incorporation | DE | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-22 03:11 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-22 03:11 UTC | Report an error |
| Business address | 23975 PARK SORRENTO, SUITE 205, CALABASAS, CA, 91302 | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-22 03:11 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-22 03:11 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$20,363,948 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-22 03:11 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $500,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquireProductiveAssets | as filed | 2026-11-22 03:11 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $361,813 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-22 03:11 UTC | Report an error |
| Form D total offering amount (D filed 2026-06-25) | $5,000,000 | 2026-06-25 | D | as filed | 2026-11-22 03:11 UTC | Report an error |
| Form D total amount sold (D filed 2026-06-25) | $5,000,000 | 2026-06-25 | D | as filed | 2026-11-22 03:11 UTC | Report an error |
| Form D industry group | Biotechnology | 2026-06-25 | D | as filed | 2026-11-22 03:11 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2026-06-25 | D | as filed | 2026-11-22 03:11 UTC | Report an error |
| Form D date of first sale | 2026-06-10 | 2026-06-25 | D | as filed | 2026-11-22 03:11 UTC | Report an error |
| Federal award transactions, fiscal year 2026 (this one registration only) | $2,441,516 | 2026-09-30 | USAspending recipient profile | as filed | 2026-11-22 03:11 UTC | Report an error |
| Number of federal award transactions, fiscal year 2026 (this one registration only) | 4 | 2026-09-30 | USAspending recipient profile | as filed | 2026-11-22 03:11 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001829126-26-012001
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | 3 months ended 2026-09-30 | 10-Q | 2026-11-05 | 0001829126-26-012001 | 2026-11-22 03:11 UTC | Report an error |
| Net income (loss) | -$4,440,209 | 3 months ended 2026-09-30 | 10-Q | 2026-11-05 | 0001829126-26-012001 | 2026-11-22 03:11 UTC | Report an error |
| Interest expense | $97,508 | 3 months ended 2026-09-30 | 10-Q | 2026-11-05 | 0001829126-26-012001 | 2026-11-22 03:11 UTC | Report an error |
| Cash and cash equivalents | $6,166,342 | at 2026-09-30 | 10-Q | 2026-11-05 | 0001829126-26-012001 | 2026-11-22 03:11 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-18 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-17 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-13 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-05 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-05 Filing 10-Q filed
- 2026-11-03 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-22 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-15 Filing 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-09-28 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-09-21 Filing 8-K filed: Item 3.03 rights of holders modified; Item 5.03 charter or bylaw amendment; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-09-17 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-09-10 Filing 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-09-10 Filing 424B5 filed
- 2026-08-21 Filing 8-K/A filed: Item 5.02 officer or director change
- 2026-08-20 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-08-13 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-12 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-10 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-10 Filing 10-Q filed
- 2026-07-15 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-07-02 Filing 8-K filed: Item 5.02 officer or director change
- 2026-06-25 Filing D filed
- 2026-06-23 Filing EFFECT filed
- 2026-06-23 Filing DEFA14A filed
- 2026-06-23 Filing DEF 14A filed
8-K item text, as filed (excerpts)
- 2026-11-18 8-K Item 7.01
Regulation FD Disclosure. On November 16, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release announcing that Amir F. Heshmatpour, the Company’s Executive Chairman, President and Chief Executive Officer, purchased an aggregate of 30,000 shares of the Company’s common stock on the open-market on November 13, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On November 17, 2026, the Company issued a press release announcing updated interim results from the Phase 2a portion of its NEO100-01 clinical study of intranasal NEO100, including an increase in the objective response rate. A copy of the press release is… the 8-K · retrieved 2026-11-22 03:11 UTC - 2026-11-17 8-K Item 7.01
Regulation FD Disclosure. NeOnc Technologies Holdings, Inc. (the “Company”) is furnishing presentation materials (the “Presentation”) that management intends to use, possibly with modifications, in one or more meetings from time to time with current and potential investors. The Presentation includes an update on the Company’s current operations and clinical development. Specifically, as shown on slides 16 and 17 of the Presentation, the Company has confirmed an additional response in the NEO100 Phase 2a study, bringing the total number of responses to 3 of 24 patients and increasing the objective response rate from 8.3% to 12.5%, as assessed using RANO 2.0 criteria. The foregoing… the 8-K · retrieved 2026-11-22 03:11 UTC - 2026-11-13 8-K Item 7.01
Regulation FD Disclosure. On November 10, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release announcing that Amir F. Heshmatpour, the Company’s Executive Chairman, President and Chief Executive Officer, purchased an aggregate of 80,000 shares of the Company’s common stock in open-market transactions on November 5, 6 and 9, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On November 11, 2026, the Company issued a press release announcing that the U.S. Food and Drug Administration granted the Company a Type B End-of-Phase meeting to discuss a potential accelerated approval pathway for intranasal NEO100 in recurrent… the 8-K · retrieved 2026-11-22 03:11 UTC - 2026-11-05 8-K Item 2.02
Results of Operations and Financial Condition. On November 5, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release reporting financial results for the third quarter ended September 30, 2026, and highlighted recent corporate and clinical progress. A copy of the press release is attached hereto as Exhibit 99.1 and the information therein is incorporated herein by reference. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of… the 8-K · retrieved 2026-11-22 03:11 UTC - 2026-11-05 8-K Item 7.01
Regulation FD Disclosure. The information under Item 2.02, above, is incorporated herein by reference. The information reported under Items 2.02 and 7.01 in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing. the 8-K · retrieved 2026-11-22 03:11 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | Cinctive Capital Management LP | $7,281,812 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:11 UTC | Report an error |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | $2,283,895 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:11 UTC | Report an error |
| 3 | BANK OF AMERICA CORP /DE/ | $1,016,586 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:11 UTC | Report an error |
| 4 | Westmount Partners, LLC | $893,216 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:11 UTC | Report an error |
| 5 | BlackRock, Inc. | $814,720 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:11 UTC | Report an error |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | $752,794 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:11 UTC | Report an error |
| 7 | VANGUARD FIDUCIARY TRUST CO | $414,404 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:11 UTC | Report an error |
| 8 | STATE STREET CORP | $195,560 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:11 UTC | Report an error |
| 9 | NORTHERN TRUST CORP | $162,496 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:11 UTC | Report an error |
| 10 | Global Retirement Partners, LLC | $125,889 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:11 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1979414.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001979414. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.